Literature DB >> 21672193

Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Barbara A Forey1, Alison J Thornton, Peter N Lee.   

Abstract

BACKGROUND: Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no previous systematic review exists. We summarize evidence for various smoking indices.
METHODS: Based on MEDLINE searches and other sources we obtained papers published to 2006 describing epidemiological studies relating incidence or prevalence of these outcomes to smoking. Studies in children or adolescents, or in populations at high respiratory disease risk or with co-existing diseases were excluded. Study-specific data were extracted on design, exposures and outcomes considered, and confounder adjustment. For each outcome RRs/ORs and 95% CIs were extracted for ever, current and ex smoking and various dose response indices, and meta-analyses and meta-regressions conducted to determine how relationships were modified by various study and RR characteristics.
RESULTS: Of 218 studies identified, 133 provide data for COPD, 101 for CB and 28 for emphysema. RR estimates are markedly heterogeneous. Based on random-effects meta-analyses of most-adjusted RR/ORs, estimates are elevated for ever smoking (COPD 2.89, CI 2.63-3.17, n = 129 RRs; CB 2.69, 2.50-2.90, n = 114; emphysema 4.51, 3.38-6.02, n = 28), current smoking (COPD 3.51, 3.08-3.99; CB 3.41, 3.13-3.72; emphysema 4.87, 2.83-8.41) and ex smoking (COPD 2.35, 2.11-2.63; CB 1.63, 1.50-1.78; emphysema 3.52, 2.51-4.94). For COPD, RRs are higher for males, for studies conducted in North America, for cigarette smoking rather than any product smoking, and where the unexposed base is never smoking any product, and are markedly lower when asthma is included in the COPD definition. Variations by sex, continent, smoking product and unexposed group are in the same direction for CB, but less clearly demonstrated. For all outcomes RRs are higher when based on mortality, and for COPD are markedly lower when based on lung function. For all outcomes, risk increases with amount smoked and pack-years. Limited data show risk decreases with increasing starting age for COPD and CB and with increasing quitting duration for COPD. No clear relationship is seen with duration of smoking.
CONCLUSIONS: The results confirm and quantify the causal relationships with smoking.

Entities:  

Mesh:

Year:  2011        PMID: 21672193      PMCID: PMC3128042          DOI: 10.1186/1471-2466-11-36

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  291 in total

1.  The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city.

Authors:  R E Mueller; D L Keble; J Plummer; S H Walker
Journal:  Am Rev Respir Dis       Date:  1971-02

Review 2.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

3.  Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts.

Authors:  J L Tang; J K Morris; N J Wald; D Hole; M Shipley; H Tunstall-Pedoe
Journal:  BMJ       Date:  1995-12-09

4.  Mortality and type of cigarette smoked.

Authors:  P N Lee; L Garfinkel
Journal:  J Epidemiol Community Health       Date:  1981-03       Impact factor: 3.710

5.  Respiratory symptoms and disease related to alcohol consumption.

Authors:  M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1981-01

6.  Longitudinal versus cross-sectional vital capacity changes and affecting factors.

Authors:  A S Dontas; D R Jacobs; A Corcondilas; A Keys; P Hannan
Journal:  J Gerontol       Date:  1984-07

7.  [Prevalence of emphysematous changes as shown by low-dose spiral CT screening images in 6144 healthy subjects].

Authors:  Takeshi Nawa; Tohru Nakagawa; Suzushi Kusano; Hajime Nakata
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2002-06

8.  [Prevalence of chronic obstructive pulmonary disease and risk factors in smokers and ex-smokers].

Authors:  J I Jaén Díaz; C de Castro Mesa; M J Gontán García-Salamanca; F López de Castro
Journal:  Arch Bronconeumol       Date:  2003-12       Impact factor: 4.872

9.  Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.

Authors:  C Alessandri; S Basili; F Violi; P Ferroni; P P Gazzaniga; C Cordova
Journal:  Thromb Haemost       Date:  1994-09       Impact factor: 5.249

10.  Comparisons of asthma, emphysema, and chronic bronchitis diagnoses in a general population sample.

Authors:  R Dodge; M G Cline; B Burrows
Journal:  Am Rev Respir Dis       Date:  1986-06
View more
  109 in total

1.  Evaluation of the cognitive behavioral smoking reduction program "Smoke_less": a randomized controlled trial.

Authors:  Tobias Rüther; Alexa Kiss; Kerstin Eberhardt; Andrea Linhardt; Christoph Kröger; Oliver Pogarell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-14       Impact factor: 5.270

2.  Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study.

Authors:  Kenneth S Kendler; Sara Larsson Lönn; Jan Sundquist; Kristina Sundquist
Journal:  Am J Psychiatry       Date:  2015-06-05       Impact factor: 18.112

3.  Chronic Bronchitis: Where Are We Now?

Authors:  Yaniv Dotan; Jennifer Y So; Victor Kim
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

Review 4.  Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer.

Authors:  Peter N Lee; Barbara A Forey; Katharine J Coombs
Journal:  BMC Cancer       Date:  2012-09-03       Impact factor: 4.430

5.  Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response.

Authors:  Eleonora Marostica; Alberto Russu; Shuying Yang; Giuseppe De Nicolao; Stefano Zamuner; Misba Beerahee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-15       Impact factor: 2.745

Review 6.  Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease.

Authors:  Julio D Antuni; Peter J Barnes
Journal:  Chronic Obstr Pulm Dis       Date:  2016-06-28

7.  Macrophage Migration Inhibitory Factor: A Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1-p38-Xanthine Oxidoreductase-Dependent Cigarette Smoke-Induced Apoptosis.

Authors:  Jonathan Fallica; Lidenys Varela; Laura Johnston; Bo Kim; Leonid Serebreni; Lan Wang; Mahendra Damarla; Todd M Kolb; Paul M Hassoun; Rachel Damico
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

8.  Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques.

Authors:  Hitendra S Chand; Rodrigo Vazquez-Guillamet; Christopher Royer; Karin Rudolph; Neerad Mishra; Shashi P Singh; Shah S Hussain; Edward Barrett; Shannon Callen; Siddappa N Byrareddy; Maria Cristina Vazquez Guillamet; Jawad Abukhalaf; Aryaz Sheybani; Vernat Exil; Veena Raizada; Hemant Agarwal; Madhavan Nair; Francois Villinger; Shilpa Buch; Mohan Sopori
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

9.  Healthy lifestyle behaviors and decreased risk of mortality in a large prospective study of U.S. women and men.

Authors:  Gundula Behrens; Beate Fischer; Simone Kohler; Yikyung Park; Albert R Hollenbeck; Michael F Leitzmann
Journal:  Eur J Epidemiol       Date:  2013-03-27       Impact factor: 8.082

10.  Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.

Authors:  Earl S Ford; David M Mannino; Anne G Wheaton; Wayne H Giles; Letitia Presley-Cantrell; Janet B Croft
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.